Asian shares mixed amid cautious outlook for global economy


Pedestrians pass the New York Stock Exchange, Wednesday, Jan. 27, 2021, in New York. Stocks are opening higher on Wall Street, keeping the S&P 500 on track for its fourth weekly gain in a row. The benchmark index was up 0.3% in the early going Friday, April 16, led by gains in banks, industrial and health care companies. (AP Photo/John Minchillo, File)

TOKYO (AP) — Asian shares were mixed Monday amid cautious optimism about a global rebound from the coronavirus pandemic.

Japan's benchmark quickly lost early gains and fell 0.1% to 29,642.79, the first market reaction after a summit by Prime Minister Yoshihide Suga with President Joe Biden over the weekend. Suga also spoke with the Pfizer chief executive, asking to ensure a more steady supply of the company's COVID-19 vaccine. Japan has lagged other nations in a vaccine rollout, with barely 1% of its population inoculated so far.

The government measures against COVID-19 infections already in some urban areas, including Tokyo, are being expanded to more parts of Japan, starting Tuesday, but the cities of Tokyo and Osaka are considering strengthening them to a “state of emergency.” Japan has never had a lockdown, and its laws would need to be changed for such action.

Australia's S&P/ASX 200 gained 0.4% to 7,093.20, while South Korea's Kospi added 0.4% to 3,212.41. Hong Kong's Hang Seng lost 0.4% to 28,856.21. The Shanghai Composite inched down 0.1% to 3,421.96.

Yoshimasa Maruyama, chief market economist at SMBC Nikko Securities, said that although the promised vaccine after Suga's U.S. visit works as a plus for Japan, their agreement to take a stiffer stance on China adds to investor worries because of China's importance for the Japanese economy.

Suga likely had hoped Biden would more forcefully expressed his support for the Tokyo Olympics, set to open in July, despite widespread public worries about the pandemic and opposition to holding the Games. The joint statement refers to the U.S. support for Japan's "efforts to hold a safe and secure" Games.

“The Suga administration has taken a risk in China relations, in accordance to the U.S. request,” Maruyama said.

On Wall Street, the S&P 500 and Dow Jones Industrial Average ended last week with new highs. The S&P 500 rose 15.05 points, or 0.4%, to 4,185.47, led by gains in companies that rely directly on consumer spending, health care stocks and banks, which benefited from higher Treasury yields.


The Dow gained 164.68 points, or 0.5% to 34,200.67. The S&P and Dow also hit all-time highs on Thursday. The technology-heavy Nasdaq inched up 13.58 points, or 0.1%, to 14,052.34 after recovering from an early slide. The Russell 2000 index of smaller companies added 5.60 points, or 0.2%, to 2,262.67.

U.S. stocks have rallied in recent weeks amid a string of encouraging reports on hiring, consumer confidence and spending that point to an accelerating U.S. economy. COVID-19 vaccinations, now reaching half of the U.S. population, and massive support from the U.S. government and Federal Reserve are fueling expectations for solid corporate profit growth as more businesses reopen.

The last round of stimulus from the government helped lift retail sales, and investors now have to weigh other proposals in Washington, which include investments in infrastructure and potential tax changes.

Investors are also focusing on the global economic recovery. Earnings reporting season is approaching, and expectations are high for companies to show they are recovering from the pandemic. Dozens of U.S. companies are report results this week, including Coca-Cola, Johnson & Johnson, Verizon Communications, Dow Chemical and American Airlines.

In energy trading, benchmark U.S. crude fell 35 cents to $62.78 a barrel. Brent crude the international standard fell 43 cents to $66.34 a barrel.

In currency trading, the U.S. dollar edged down to 108.74 Japanese yen from 108.86 yen. The euro cost $1.957, down from $1.1978.

Should you invest $1,000 in Johnson & Johnson right now?

Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Pfizer (PFE)
4.9742 of 5 stars
$25.38+0.5%6.62%70.50Hold$36.33
Johnson & Johnson (JNJ)
4.9283 of 5 stars
$146.13-0.5%3.26%9.11Hold$175.86
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Johnson & Johnson's Dip is a Strategic Buy Point for Investors

Johnson & Johnson's Dip is a Strategic Buy Point for Investors

JNJ shares hit a low, trading near $145 at under 14X earnings. With a high dividend yield, it's poised for a rebound.

Search Headlines: